标题
Polo-like kinases and acute leukemia
作者
关键词
-
出版物
ONCOGENE
Volume -, Issue -, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-08-13
DOI
10.1038/s41388-018-0443-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo
- (2018) Ulrike Tontsch-Grunt et al. CANCER LETTERS
- Presenting national HIV/AIDS and sexually transmitted disease research in Brazil
- (2018) Adele Schwartz Benzaken et al. MEDICINE
- PLK4: a link between centriole biogenesis and cancer
- (2017) Radhika Radha Maniswami et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers
- (2017) Stine N. Nielsen et al. PEDIATRIC BLOOD & CANCER
- Plk4 Promotes Cancer Invasion and Metastasis through Arp2/3 Complex Regulation of the Actin Cytoskeleton
- (2016) Karineh Kazazian et al. CANCER RESEARCH
- Polo-like kinase inhibitors in hematologic malignancies
- (2016) Chetasi Talati et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Targeting the mTOR Pathway in Leukemia
- (2016) Shira Dinner et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Expression of Polo-Like Kinase 4(PLK4) in Breast Cancer and Its Response to Taxane-Based Neoadjuvant Chemotherapy
- (2016) Zhenhua Li et al. Journal of Cancer
- Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain
- (2015) Andrej Scharow et al. CHEMBIOCHEM
- Molecular Targeting of the Oncoprotein PLK1 in Pediatric Acute Myeloid Leukemia: RO3280, a Novel PLK1 Inhibitor, Induces Apoptosis in Leukemia Cells
- (2015) Na-Na Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia
- (2015) C. Michel Zwaan et al. JOURNAL OF CLINICAL ONCOLOGY
- The deregulated promoter methylation of thePolo-like kinasesas a potential biomarker in hematological malignancies
- (2015) Alejandra Ward et al. LEUKEMIA & LYMPHOMA
- Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines
- (2015) Claudia Münch et al. LEUKEMIA RESEARCH
- Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy
- (2015) Kyung S. Lee et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Enhanced cellular uptake of a TAT-conjugated peptide inhibitor targeting the polo-box domain of polo-like kinase 1
- (2014) Sung Min Kim et al. AMINO ACIDS
- Declining childhood and adolescent cancer mortality: Great progress but still much to be done
- (2014) Kathy Pritchard-Jones et al. CANCER
- Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia
- (2014) Antonino Maria Spartà et al. CELL CYCLE
- Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance
- (2014) Mihaela Marina Frontiers in Bioscience-Landmark
- Aging and Risk of Severe, Disabling, Life-Threatening, and Fatal Events in the Childhood Cancer Survivor Study
- (2014) Gregory T. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
- (2014) B T Gjertsen et al. LEUKEMIA
- Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications
- (2014) Bryan R Meade et al. NATURE BIOTECHNOLOGY
- The Childhood Leukemia International Consortium
- (2013) Catherine Metayer et al. Cancer Epidemiology
- Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain
- (2013) G. Osca-Gelis et al. HAEMATOLOGICA
- TrkC promotes survival and growth of leukemia cells through Akt-mTOR-Dependent Up-Regulation of PLK-1 and Twist-1
- (2013) Min Soo Kim et al. MOLECULES AND CELLS
- Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program
- (2013) Richard Gorlick et al. PEDIATRIC BLOOD & CANCER
- The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia
- (2013) Alessia Casolaro et al. PLoS One
- Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series
- (2012) R. Fruscio et al. ANNALS OF ONCOLOGY
- A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
- (2012) K Mross et al. BRITISH JOURNAL OF CANCER
- PLK1 Inhibitors Synergistically Potentiate HDAC Inhibitor Lethality in Imatinib Mesylate-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo
- (2012) G. Dasmahapatra et al. CLINICAL CANCER RESEARCH
- Polo-like kinase-1 regulates kinetochore–microtubule dynamics and spindle checkpoint silencing
- (2012) Dan Liu et al. JOURNAL OF CELL BIOLOGY
- Plk1 negatively regulates PRC1 to prevent premature midzone formation before cytokinesis
- (2012) Chi-Kuo Hu et al. MOLECULAR BIOLOGY OF THE CELL
- NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies
- (2012) B. Valsasina et al. MOLECULAR CANCER THERAPEUTICS
- Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions
- (2011) Leonidas Benetatos et al. ANNALS OF HEMATOLOGY
- An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies
- (2011) Kristina Spaniol et al. ANTI-CANCER DRUGS
- Plk2 regulated centriole duplication is dependent on its localization to the centrosome and a functional polo-box domain
- (2011) Onur Cizmecioglu et al. CELL CYCLE
- From Plk1 to Plk5
- (2011) Guillermo de Cárcer et al. CELL CYCLE
- Modern Therapy of Acute Lymphoblastic Leukemia
- (2011) Renato Bassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Plk5, a Polo Box Domain-Only Protein with Specific Roles in Neuron Differentiation and Glioblastoma Suppression
- (2011) G. de Carcer et al. MOLECULAR AND CELLULAR BIOLOGY
- Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells
- (2011) Monika Raab et al. Nature Communications
- The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation
- (2009) Li Li et al. ACTA PHARMACOLOGICA SINICA
- Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells
- (2009) A. G. Renner et al. BLOOD
- Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response
- (2009) Emeline de Viron et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Pan-Specific Inhibitor of the Polo-Box Domains of Polo-like Kinases Arrests Cancer Cells in Mitosis
- (2009) Wolfgang Reindl et al. CHEMBIOCHEM
- BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
- (2009) D. Rudolph et al. CLINICAL CANCER RESEARCH
- Plk3 inhibits pro-apoptotic activity of p73 through physical interaction and phosphorylation
- (2009) Meixiang Sang et al. GENES TO CELLS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started